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Strengths and limitations of this study
 ► The study will provide a reliable and reinforced 
tool (the PAINAD scale) to assess pain in elderly 
people with cognitive impairment and inability to 
communicate which will facilitate the correct pain 
management.
 ► The determination of biomarkers of pain in sali-
va is a promising tool because it is a noninvasive 
and inexpensive method that provides information 
and complements the information provided by the 
PAINAD scale.
 ► The results of the present study will lead to an im-
provement in quality of life of these patients and 
their families thanks to a better diagnosis of pain 
using the PAINAD scale and the salivary biomarkers.
 ► The correlation of the information provided by the 
PAINAD scale and the values of the salivary biomark-
ers will allow health institutions to make clinical rec-
ommendations with a higher level of evidence.
ABSTRACT
Introduction Pain is an under- diagnosed problem in elderly 
people, especially in those with cognitive impairment who are 
unable to verbalise their pain. Although the Pain assessment in 
advanced dementia scale (PAINAD) scale is a tool recognised 
for its clinical interest in this type of patients, its correlation 
with the saliva biomarkers reinforced its utility. The aim of this 
research will be to correlate the scores of this scale with the 
levels of biomarkers of pain found in saliva samples of patients 
with cognitive impairment and inability to communicate.
Methods and analysis This is an observational study. 
The level of pain will be evaluated using the PAINAD scale. 
Moreover, pain biomarkers, in particular secretory IgA and 
soluble tumour necrosis factor receptor type II, will be 
determined in saliva. Both assessments will be conducted 
in 75 patients aged over 65 years with advanced 
cognitive impairment and inability to communicate. The 
PAINAD scores will be correlated with the levels of these 
biomarkers of pain. A control group consisting of 75 
healthy subjects aged over 65 years will be included in the 
study. Moreover, sociodemographic variables and variables 
related to pain, dementia and other clinical conditions 
will be recorded. The analysis will be performed with the 
statistical package SPSS V.22 and the software R.
Ethics and dissemination The study has been reviewed 
and approved by the Andalusian Human Research Ethics 
Committee. In addition, this study has been financed by 
the Junta de Andalucía through a regional health research 
fund (Research code: PI-0357–2017). The results will be 
actively disseminated trough a high- impact journal in our 
study area, conference presentations and social media.
InTRoduCTIon
The assessment of pain in elderly people with 
cognitive impairment is often insufficient and, 
consequently, pain treatment is inadequate.1–4
Although elderly patients with cognitive 
impairment are not the only underdiagnosed 
and undertreated group, they are undoubt-
edly one of the most affected. The reasons 
are mainly two:
1. Elders are more likely to experience pain.5
2. Elders usually have difficulty communi-
cating the level of pain they are suffering 
to their caregivers and healthcare provid-
ers.3 6–8
Pain is a frequent experience for many 
elderly people.5 Most common chronic 
diseases afflicting the elderly, such as depres-
sion, cardiovascular disease, cancer and 
osteoporosis, involve a larger risk of devel-
oping chronic pain.4 9 Approximately 50% of 
community dwelling adults and up to 80% of 
institutionalised older adults are estimated to 
experience considerable pain.7 10
In addition, pain has important conse-
quences in the elderly population, because it 
affects them both physically and psychologi-
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situations. Pain causes long- term problems affecting, in 
general, to quality of life.6
However, despite being a frequent and important 
problem, studies have shown that pain is often not evalu-
ated or treated correctly, especially in the elderly.
Numerous studies have also shown that older people 
with cognitive impairment, particularly with dementia, 
often suffer from painful illnesses (specifically, it is esti-
mated that between 80% and 85% of them suffer pain) 
and that they are usually prescribed fewer analgesics than 
patients with intact cognitive abilities.2 3 11
This undertreatment is undoubtedly related to the 
difficulty of detecting pain in this population, mainly due 
to the loss of verbal abilities to express pain,3 or to insuf-
ficient instruction or training of professionals and care-
givers to identify pain.12
The tools used to assess pain can be classified into: (1) 
self- reports of pain; (2) direct observation of the person’s 
behaviour and (3) biomarkers.
Self- reports are considered the most reliable and 
refined measure of the presence and intensity of pain, 
even in patients with moderate dementia.13 However, 
when the capacity for abstract reasoning is low, the use 
of such scales, even though they are very simple, becomes 
very complicated, because patients do not understand 
the concepts used. This complexity becomes impossible 
to use when, in addition, the ability of verbal communica-
tion is affected.
As an alternative to verbal evaluation (or self- report), a 
significant number of observational scales have been devel-
oped in the last 15 years. Several literature review studies 
describe more than 24 tools of this type14–21 and although 
none of the tools can be recommended based on existing 
evidence, several studies advocate the inclusion of any of 
them within a comprehensive pain care protocol.1 10 22–25
Among them, the PAINAD scale is recommended by the 
National Nursing Home Pain Collaborative as a clinically 
useful tool,26 and several authors describe the PAINAD as 
the most practical and promising scale.8 19 27–30 The PAINAD 
scale has a convergent validity and a moderate internal 
consistency.31 32 The scores obtained with the PAINAD scale 
vary when performing a potentially painful activity;32 33 and 
the scores decrease after the administration of analgesics.2 
Despite this, the validation of the PAINAD scale to Spanish 
is not complete.
The determination of biomarkers of pain is the third of 
the potential tools. Their determination in saliva would be 
an enormously useful, noninvasive and economic tool. In 
fact, some pain biomarkers have already been determined in 
saliva,34 35 such as salivary cortisol, its salivary levels correlate 
strongly with the level of pain,36 salivary α-amylase,37 secre-
tory IgA (sIgA),38 testosterone39 or tumour necrosis factor 
receptor type II (sTNF- RII).40 The saliva levels of sTNF- RII 
correlate significantly with its levels in plasma.41 However, 
authors such as Sobas et al42 point to sIgA and sTNF- RII, out 
of all these biomarkers, as potential salivary markers of pain 




The aim of this research will be to correlate the scores 
of the PAINAD scale with the levels of pain biomarkers 
in saliva samples obtained from patients with cognitive 
impairment. The objectives of the study will be to:
1. Evaluate the pain level through the PAINAD scale.
2. Determine in saliva the values of the pain biomarkers 
sTNF- RII and sIgA in a population with cognitive im-
pairment and communication inability.
3. Identify the possible relation between sociodemo-
graphic and clinical variables and the PAINAD score 
and the values of pain biomarkers in saliva.
Research hypothesis
We anticipate that the PAINAD score will correlate with 
the salivary levels of sTNF- RII and sIgA in the sample. 
The correlation level will be established between the final 
score on the scale and the presence of significant differ-
ences in these biomarkers.
Study design
This is an observational study which began in May 2018 
and will end in June 2020. The design followed the 
Strengthening the Reporting of Observational Studies in 
Epidemiology recommendations.
This study is funded by the Health Department of the 
Regional Government of Andalusia (PI-0357–2017).
Study setting
A health district of an Andalusian province, through its 
network of Primary Healthcare centres and an institution 
dedicated to the care of patients with dementia, specifi-
cally, with Alzheimer’s disease.
Participants and selection criteria
The sample size has been calculated for a correlation 
magnitude of r=0.3, a statistical CI of 95%, a statistical 
power of 80%, with a unilateral approach and a 10% of 
losses. The result sample size is 75 subjects.
The inclusion criteria for participants were the 
following:
 ► Age≥65 years.
 ► Medical diagnosis of dementia or Alzheimer’s disease 
with a Global Deterioration Scale (GDS) score 
between 5 and 7.43
 ► Being unable to communicate verbally.
 ► Having a relative or legal representative that can sign 
the informed consent for the participation of the 
patient in the study.
 ► Being included, at least, for 3 months in the listings 
of the dementia process. In the case of the institution 
dedicated to the care of patients with Alzheimer’s 
disease, patients who have used this service for at least 
3 months will be included.
The recruitment of the participants will be conducted 
consecutively by the interventional nurses belonging to 
the different participating primary healthcare centres, 
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Table 1 Study measures
Sociodemographic data Clinical history
Health variables Clinical history
Pharmacological treatments Clinical history
Cognitive impairment GDS
Autonomy in activities of daily living Barthel Index
PAINAD Observational scale
Biomarkers Saliva collection
GDS, Global Deterioration Scale.
consultation based on the lists of the dementia process 
of the urban health centres (HC) and an institution dedi-
cated to the care of Alzheimer’s patients.
Subjects without cognitive impairment, within the same 
age range, who voluntarily wish to participate in this study, 
will be investigated to correlate the values obtained in 
the PAINAD with the determination of pain biomarkers. 
These 75 control subjects will be recruited from the envi-
ronment close to the subjects (family, relatives and other 
users of the same HC).
Study measures
The main variables will be the scores of the Spanish version 
of PAINAD and the determinations of the biomarkers 
sTNF- RII and IgAs. Other study variables will be the scores 
of the GDS scale; sociodemographic variables (age and 
sex); clinical data related to pain (duration, frequency, 
location, aetiology, type of analgesic treatment, adjuvant 
treatment and pain control at the current time) and level 
of autonomy in basic activities of daily living (table 1).
data collection
A specific Book for Data Collection (BDC) will be 
provided to each researcher. An explaining manual for 
the BDC has been developed for standardised data collec-
tion to ensure the quality of data collection. In addition, 
the professionals will receive face- to- face training about 
data collection and the tools or assessment scales to 
ensure the validity and reproducibility.
The professionals will also be individually instructed 
on how to perform the saliva collection using the passive 
secretion method:44
1. One hour prior to sample collection, subjects should 
not eat, drink (except water), chew gum, brush their 
teeth, consume caffeine or do physical exercise.
2. Five minutes prior to sample collection, the subject 
should rinse their mouth with clean water to reduce 
the contamination of saliva with food debris.
3. All existing saliva in the mouth should be swallowed 
before starting the sample collection.
4. Subsequently, intermittently deposit the accumulated 
saliva for a period of 5 min in a collection tube, requir-
ing at least 1 mL. If the 5 mL collection tube is filled 
before 5 min, the amount of time that has elapsed is 
recorded.
Voluntary written informed consent will be obtained 
from a family member or their legal representative in the 
case of patients with cognitive impairment, and directly 
from the control group subjects. Once the consent is 
received, the researcher will collect the sociodemographic 
and clinical data of the patient. The PAINAD scale will 
be completed along with the other selected measures. In 
addition, saliva will be collected.
Samples will be collected in a clinical setting, under 
supervision, between 09:00 and 10:00 in the morning 
and always before the morning medication is taken. The 
samples collected will always be refrigerated, and will 
be collected always in the same room, where tempera-
ture and humidity will be recorded. After collection, the 
samples will be frozen at −80°C until analysis.
Data will be collected by qualified personnel previously 
instructed under the aforementioned protocol.
determination of sTnF-RII and IgA
The determination of sTNF- RII and IgAs levels will be 
performed using an ELISA. The sTNF- RII levels will be 
determined using the Human sTNF- RII Quantikine 
ELISA kit (R&D Systems, Minneapolis, MN) and the IgAs 
using the sIgA ELISA kit (Salimetrics LLC, State College, 
Pennsylvania, USA). The collection period will be deter-
mined because IgA levels depend on the flow of saliva 
secretion. The quantification of total proteins in saliva 
will be performed using Bradford’s method, using bovine 
serum albumin as standard.
data analysis
For the description of the sample, the number of observa-
tions, mean, SD, minimum, maximum, median, IQR and 
95% CI for the mean value will be used for quantitative 
variables; whereas the absolute and relative frequencies 
will be used for categorical variables (for this type of vari-
ables, the lost data will appear as another category, with its 
absolute frequency and its percentage).
In order to determine the degree of relationship 
between the PAINAD scale and the values of the 
biomarkers considered, the matrix of polyserial correla-
tions with their corresponding hypothesis contrasts will 
be used. A logit model will be used to determine which 
biomarker most affects the pain condition and multi-
nomial logistic models will be considered to determine 
which of the two biomarkers has the strongest influence 
on pain gradation.
Next, to determine the possible relationships between 
demographic and clinical variables with PAINAD scores 
and biomarkers, Pearson and polyserial correlations will 
be obtained depending on the scales considered (contin-
uous and ordinal), as well as the χ2 coefficient or predic-
tive coefficients lambda (nominal and ordinal), with their 
corresponding significances levels. Finally, in the case of 
detecting some type of relationship between these vari-
ables, they will be introduced in the logit and logistic 
multinomial models to determine their relative influence 
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This analysis will be carried out using the statistical package 
SPSS V.22 for most calculations and the software R for the 
determination of the coefficients of polyserial correlations. 
For all cases, a significance of 5% will be assumed.
Patient and public involvement
The research question for this study was developed 
based on a synthesis of the recent literature, therefore 
patients and the public were not involved in the design 
of the study, including the research question, outcomes 
measures, recruitment to or conduct of the study. The 
results of the study will be actively disseminated and made 
available to the heads of the participating centres.
dISCuSSIon
The severe ageing of global population has caused a 
significant increase in the prevalence of cognitive impair-
ment. However, the importance of these figures is not due 
solely to the current transcendence of this public health 
problem, but also it is due to the fact that multiple studies 
indicate that the percentage of people with dementia will 
increase substantially in the coming years.45
In this context, healthcare systems, particularly in 
Western countries, face new challenges in the care of 
patients with cognitive impairment, among them the 
assessment and adequate management of pain are signif-
icant, needing solutions to provide quality care to this 
population.
Pain in patients with cognitive impairment is an unre-
solved problem due to the progression of the neurolog-
ical disorders that they present and that entails the loss 
of the ability to communicate, which makes it difficult to 
manage pain and, therefore, it leads to pain underdiag-
nosis and undertreatment.12
The PAINAD scale is a tool of acknowledged utility for 
the assessment of pain in people with cognitive impair-
ment and communication inability.46
The determination of pain biomarkers in saliva is a tool 
of maximum utility because of its non- invasiveness and 
improved accessibility to the biological sample in compar-
ison with blood determinations, becoming a rigorous and 
accurate assessment tool thanks to which patient’s pain 
can be detected and addressed.
The correlation of the results of both tools will allow 
health professionals, as well as relatives and informal care-
givers of these patients, to know that pain can be evalu-
ated correctly, allowing a better use of analgesia.
limitations
The selection of the subjects studied may be affected 
by consecutive sampling. However, no previous list of 
patients, not even an estimate of the total number of 
patients meeting the established inclusion criteria, was 
available for the studied location.
In addition, the recruitment process may be affected by 
the non- acceptance of those relatives of patients who do 
not want to participate in the study.
Finally, it is necessary to point out that the test–retest has 
the limitation of the changing nature of pain. Although 
the study is designed for the chronic pain condition, it 
is inevitable that cases of acute pain are found and that, 
therefore, the score changes, even when there is a narrow 
margin between the two measurements. These cases of 
acute pain will undoubtedly represent a distortion in the 
verification of this feature.
EThICS And dISSEMInATIon
All participants will be informed of the general aspects of 
the study. Participants have the right to withdraw consent 
to participate at any time.
Moreover, all the participants must sign a written 
informed consent before participating in the study. Confi-
dentiality is guaranteed.
The study will comply with the requirements set out by 
the Regulation (EU) 2016/679 of the European Parlia-
ment and of the Council of 27 April 2016 on General 
Data Protection Regulation (GDPR).
The plans to disseminate the results of this observational 
study include publishing at least a research paper in peer- 
reviewed journals in our study area. Also, if possible, the 
results of this research will be presented in conference 
presentations.
ConCluSIon
The results of this research will allow elucidating the 
concentrations of pain biomarkers in saliva, which would 
be an objective tool of enormous utility to confirm the 
possible diagnosis of pain in this population. The correla-
tion between the values of the PAINAD scale and those of 
the pain biomarkers obtained in saliva samples will reflect 
the complementarity of both tools for the assessment of 
pain and will reinforce the suitability of the scale in rela-
tion to the evaluation of pain in this population.
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